Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great read! Thanks for sharing.
Let me guess you are short AMRN? Lmao. Too funny.
Hurry and cover man.
Long term I believe it will get taken out. Unlike AMRN that management team has a history of getting companies sold to larger entities.
PS: you sound like a hater now that our share price is rising. Don’t be a hater. Nobody likes haters. Lol
Worked out great for me. It was a 3 bagger last year. I sold in the $20s and buying back at these levels again. Rinse and repeat. :)
Great post!!
Thomas Barton a great investor and who was one of the first to predict the short squeeze in Game Stock just called out Amarin in a tweet. Thom and his brother run a hedge fund in Dallas and are close with Michael Dell.
FYI. https://mobile.twitter.com/ThomasUBarton1/status/1486191936046186497?cxt=HHwWgoCqgaLsgaApAAAA
His tweet:
“If you don’t own $amrn, you don’t know who Alex Denner is, the perfect balance sheet with $500 mil in cash, and a very good drug that’s hard to knock off and patent protected overseas. It’s a 7x and trades at a no lose entry point. It’s going to $20. Probably in a straight line.”
Amarin is getting attention.
I bet they already have a buyer in mind the change of control is going to be the "key" to unlocking this and moving forward with their plans.
That would be amazing given we are sub $4.
Will be interesting to see how and when the SP gets going....
All great news.
And don't forget a Big Pharma's ability to "correct" this generic problem in the USA with the FDA. A Big Pharma has leverage with the FDA...A small pharma (fry) like AMRN not so much.
See how Biogen was able to get Adhulem approved.
So glad to see Denner on BOD. Our Chairman of the BOD needs to be tossed out ASAP.
Shareholders own the company.
When do you think this saga ends? Q2 of this year? Q3 of this year? or are we talking next year....2023...
He runs a hedge fund. Me thinks he will aim to maximize value as much as possible.
He's not in it for a single.
Wall Street Bets---we need them to find out about Denner's latest filing.....that's the ammunition we need.
There's an inherent conflict of interest. Management works for the shareholders and not the other way around.
Management wants to continue collecting their checks / salaries etc.
For what? What value have they created. It's sickening.
Glad Denner is on BOD. I hope they spilled their coffee when they saw his filing.
It's great news. Our BOD is weak.
And remember the trolls on stock twits posted erroneously Denner was out when the class action law suits were out in full force.
Ignore the trolls on stock twits.....
Alex Denner / Sarissa stepping up big time. Let's GOOOOOOOO!
Get these bums off the BOD
But generics would not be able to use this in USA right if Amarin has the rights from Mochida?
Larrybirdlegend—you stil here? Would be great to get your updated thoughts on things.
LBL--curious as to what your hedge fund neighbors think about us being pinned below $4? $3.50 for that matter.
That was from a new account created Jan 10th, 2022. Likely FUD
When? How can we get above $20 when we are sub $4. SMH
Got it. Thanks.
So you think Wall Street will grasp it?
Very strong!! All great points!
Are you still holding strong here?
What’s your sense of Pfizer’s interest with Vascepa/HLS in Canada? Seems now would be the opportune time to make a play on AMRN at these depressed prices.
Happy New Year to you. But our stock price is at $3.40. Wall Street does not care.
What’s with the continued silence from management? They are running a public company not working in a library.
LBL what is your recent take on things?
That's not true.
Which makes me wonder what else have you been lying about.....?
When will news of approval in China hit? With our luck it will be Dec. 31st lol
I am glad and thrilled Alex Denner is on board. He is not here for the shenanigans ("it works"). Unlike the last CEO, he is here to do what's right for shareholders. Shareholders own the company and the BOD and management have a fiduciary duty to see to it that shareholder value is created.
Happy to have Denner on board.
The Company is not a piggy bank for the executive team.
Small cap biotechs have been wrecked.
Joe Edelman / Perceptive Advisors arguably one of the best biotech investors in the world is down over 30 percent this year.
He rarely has a losing year.
Larrybirdlegend--it would be great to hear from you. Share price has been absolutely decimated. And here we are 2 weeks before 2022.
Thoughts?
Does KM get it that this needs to be in the hands of a BP?
congrats for hanging on!
WSJ's write-up of the Pfizer acquisition of ARNA. Interesting ARNA's drug is expected to bring in $900 mm of revenue by 2026. ARNA's stock declined 35% this year.
Pfizer Inc. PFE +3.98% agreed to acquire Arena Pharmaceuticals Inc. ARNA +81.03% for $6.7 billion, bolstering the pharmaceutical giant’s pipeline of medicines for inflammatory bowel diseases.
Pfizer will pay Arena shareholders $100 per share, double Arena’s share price of $49.94 through Friday’s close. The stock had fallen 35% so far this year before the Pfizer acquisition was announced.
Pfizer will gain Arena’s lead drug, etrasimod, a pill in late-stage studies in ulcerative colitis; results are expected in the first quarter of next year, according to analysts. Data from a midstage study in Crohn’s disease are expected in the second quarter of 2022. The drug could have global ulcerative colitis sales of $900 million by 2026, BMO Capital Markets said in a note to clients.
“We plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases,” said Mike Gladstone, Pfizer’s global president for inflammation and immunology.
Newsletter Sign-up
Coronavirus Briefing and Health Weekly
Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.
SUBSCRIBE
If approved, Arena’s etrasimod would compete with Bristol-Myers Squibb & Co.’s Zeposia, a pill with a similar biological function targeting immune cell receptors. Zeposia was approved in May for ulcerative colitis by the Food and Drug Administration. Global Zeposia sales are forecast to reach $2.9 billion in 2025, according to SVB Leerink, an investment bank.
There are about a quarter-million ulcerative colitis patients in the U.S. receiving treatment, according to Leerink. More than half of patients take drugs to block an inflammatory protein called tumor necrosis factor, such as AbbVie Inc.’s Humira.
Pfizer’s Xeljanz, which targets a different inflammatory protein, had $500 million in 2020 sales from patients with ulcerative colitis or Crohn’s disease, according to Leerink. Xeljanz had $2.44 billion in global sales last year.
Arena, based in Park City, Utah, has reinvented itself in recent years after an anti-obesity drug it developed flopped in the marketplace. After selling rights to the drug, Belviq, to Eisai Co. in 2017, Arena assembled a new pipeline aimed at inflammatory diseases such as Crohn’s disease and eczema. Eisai pulled the drug off the market early last year because of safety risks.
Analysts say the deal could be the first of many for Pfizer, which had $27.7 billion in cash and short-term investments at the beginning of October. The company’s revenue more than doubled in the third quarter, with the biggest contribution coming from $13 billion in sales of its Covid-19 vaccine.
BMO Capital Markets analyst Evan Seigerman said in a note to clients on Monday that Pfizer has the ability to do $132 billion in deals through 2022. “We see this as the first of many deals for Pfizer,” he said. “Pfizer is making good use of the deluge of cash from Covid-19 vaccines/boosters to further bolster its pipeline.”
The deal is expected to close in the first half of 2022, pending regulatory approvals.
Write to Joseph Walker at joseph.walker@wsj.com
Main thing is ruling on the motion to dismiss. These delays are not material.
The ruling on the motion to dismiss is the important thing.
Thanks for the intel. In Southern California, CVS does not have generic in stock. Branded was given to me.
Can you elaborate more on how this is done?
With all due respect, we are sitting at $3.49 as I type this.
And we are a few weeks away from 2022.
Wall Street does not seem to care about this stock.
Posted on stocktwits that Eddingpharm has added jobs in China.
https://eddingpharm.m.zhiye.com/#/jobs?jc=1&c1=-1&c2=-1&ky=
I cannot find the English translation on the page however.
See stocktwits
thanks. where do you get this info from?